Almirall licenses European rights to GW's Sativex
Executive Summary
GW Pharmaceuticals PLC, a company researching the therapeutic effects of cannabis, licensed to Spanish pharma Almirall Prodesfarma SA European marketing rights (outside of the UK) to the Phase III cannabis-based drug candidate Sativex.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice